Thomas Russo
Gardner Russo & Quinn
Thomas Russo Novartis AG ADR stake
total: 273
Gardner Russo & Quinn NVS trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2017 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2018 Q1
According to 2026 Q2 report, Thomas Russo doesn't hold any Novartis AG ADR (NVS) shares. To date, the estimated cost basis is nearly $80 for "buy" trades and estimated average "sell" price is $80. Gardner Russo & Quinn first purchased NVS in 2017 Q4, initially acquiring 125 shares. Since the initial investment in Novartis AG ADR (NVS), Gardner Russo & Quinn has made 1 more transaction.
When did Thomas Russo sell Novartis AG ADR (NVS)?
Thomas Russo sold off the entire Novartis AG ADR (NVS) position in 2018 Q1.
When did Thomas Russo buy Novartis AG ADR (NVS)?
Thomas Russo first invested in Novartis AG ADR (NVS) in 2017 Q4 at the reported quarter-end price of $80.00 per share.
What's the cost basis of Gardner Russo & Quinn's NVS stake?
The estimated cost basis for Novartis AG ADR (NVS) stake is around $80.00 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $80.00
- Weighted AVG sell price:
- $80.00
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.